| Date | Title | Description | Source |
| 25.04.2024 | Innovent to Present Clinical Data of Multiple Novel Molecule... | SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim a... | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molec... | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 02.04.2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in Chi... | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 27.03.2024 | Innovent Dosed First Participant in Phase 3 Clinical Study (... | ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZ... | en.prnasia... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZ... | salamancap... |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase ... | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("In... | en.prnasia... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molec... | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 07.03.2024 | Innovent released the results of two clinical studies of IBI... | ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 05.03.2024 | Innovent and AnHeart Therapeutics Announce the NMPA of China... | ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 01.03.2024 | Innovent Announces First Participant Dosed in a Phase I Stud... | ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 20.02.2024 | Innovent Announces Primary Endpoint Met in the Phase 3 Clini... | ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 07.02.2024 | Innovent's First New Drug Application of Mazdutide for Chron... | ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 22.11.2023 | Innovent Announces Publication of Mazdutide (IBI362) Phase 2... | ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (H... | en.prnasia... |
| 06.11.2023 | Innovent Presents Clinical Data of Two Ophthalmic Bispecific... | ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 30.10.2023 | Innovent Announces Robust Weight Loss Efficacy, Multiple Met... | Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG recept... | en.prnasia... |
| 28.09.2023 | IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA ... | 82.4% of patients without prior CAR-T achieving Complete Response (CR) or better
SHANGHAI and NANJIN... | en.prnasia... |
| 26.06.2023 | Innovent and RemeGen Enter into Clinical Trial Collaboration... | ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 12.06.2023 | Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-... | ROCKVILLE, Md. and SUZHOU, China, June 12, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 06.06.2023 | Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C ... | ROCKVILLE, Md. and SUZHOU, China, June 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 06.06.2023 | Promising 2-year updated data from cadonilimab presented at ... | HONG KONG, June 6, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") released two-year ... | en.prnasia... |
| 05.06.2023 | Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG... | ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 03.06.2023 | Innovent Announces the Second Breakthrough Therapy Designati... | ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 02.06.2023 | Innovent Enters into Clinical Trial Collaboration with Merck... | ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 17.05.2023 | Innovent Announces Clinical Data of Multiple Trials Will be ... | ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 15.05.2023 | Innovent Receives NMPA Breakthrough Designation for IBI351 (... | ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 10.05.2023 | The China NMPA Approves TYVYT® (sintilimab injection) in Com... | ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 08.05.2023 | Innovent Updates the Results from the ORIENT-31 Study of Sin... | ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 08.05.2023 | Innovent Announces First Participant Dosed in Phase 3 Study ... | ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 20.04.2023 | Innovent Announces Overall Survival Results of Phase 2 Study... | ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 18.04.2023 | Innovent Announces Updated Data of Phase 1 Clinical Trial fo... | ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 18.04.2023 | Innovent Releases Final Analysis Results of ORIENT-16: the P... | ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 17.04.2023 | Innovent Releases Final Analysis Results of ORIENT-15: the P... | ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 29.03.2023 | Innovent Announces 2022 Annual Results and Business Updates | Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capabilit... | en.prnasia... |
| 21.03.2023 | Innovent Announces Clinical Data of Multiple Trials Will be ... | ROCKVILLE, Md. and SUZHOU, China, March 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | einpresswi... |
| 21.03.2023 | Innovent Announces Clinical Data of Multiple Trials Will be ... | ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn... | en.prnasia... |
| 28.02.2023 | Innovent Announces First Participant Dosed in Phase 1 Clinic... | ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 16.02.2023 | Innovent Announces First Patient Dosed in a Phase 3 Clinical... | ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("In... | en.prnasia... |
| 15.02.2023 | Innovent Announces First Participant Dosed in Phase 2 Study ... | ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 19.01.2023 | China's First and Only Approved Third-Generation BCR-ABL Inh... | SUZHOU, China, and ROCKVILLE, MD, Jan. 19, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global... | en.prnasia... |
| 18.01.2023 | Innovent Announces Inclusion in the China National Reimburse... | ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 11.01.2023 | Innovent Announces First Participant Dosed in a Phase 3 Clin... | ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 10.01.2023 | Innovent Announces First Participant Dosed in a Phase 3 Clin... | ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 06.01.2023 | Innovent Announces the National Medical Products Administrat... | ROCKVILLE, Md. and SUZHOU, China, Jan. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 05.01.2023 | Innovent Announces NMPA's Breakthrough Therapy Designation f... | ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 05.01.2023 | Innovent to Present at 41st Annual J.P. Morgan Healthcare Co... | ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 15.12.2022 | Innovent and LG Chem Announce Strategic Collaboration for Ti... | ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent&q... | en.prnasia... |
| 11.12.2022 | Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD4... | ROCKVILLE, Md. and SUZHOU, China, Dec. 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 11.12.2022 | Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD4... | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | einpresswi... |
| 09.12.2022 | Innovent Presents Phase Ib Clinical Data Update of IBI110 (A... | ROCKVILLE, Md. and SUZHOU, China, Dec. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 05.12.2022 | UNION therapeutics and Innovent announce first subject dosed... | UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of ... | news.cisio... |
| 05.12.2022 | Innovent and UNION Therapeutics Announce First Subject Dosed... | ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 28.11.2022 | Innovent Announced Clinical Data of Multiple Trials Will be ... | ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 15.11.2022 | Innovent Announces First Participant Dosed in a Phase 3 Clin... | ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 14.11.2022 | Innovent Presents Clinical Data of Phase Ia Study for IBI351... | ROCKVILLE,M.D. and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 07.11.2022 | Innovent Releases Results of a Phase 3 Clinical Study of Taf... | ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (... | en.prnasia... |
| 31.10.2022 | Innovent Announces First Patient Dosing in Australia in Phas... | ROCKVILLE, Md. and SUZHOU, China, Oct. 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 17.10.2022 | Innovent Announces Phase Ib Results of Higher-dose Mazdutide... | ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 17.10.2022 | Innovent Announces Phase Ib Results of Higher-dose Mazdutide... | ROCKVILLE, Md. and SUZHOU, China, Oct. 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | einpresswi... |
| 10.10.2022 | The China NMPA Approved CYRAMZA® (ramucirumab) for the Treat... | ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 10.10.2022 | The China NMPA Approves Selpercatinib for the Treatment of P... | ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 08.09.2022 | Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Ben... | ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 05.09.2022 | Innovent Announces First Participant Dosed in the Higher-dos... | ROCKVILLE, Md. and SUZHOU, China, Sept. 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | einpresswi... |
| 05.09.2022 | Innovent Announces First Participant Dosed in the Higher-dos... | ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ... | en.prnasia... |
| 25.08.2022 | Innovent Announced 2022 Interim Results and Business Updates | Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutical Com... | en.prnasia... |
| 24.08.2022 | Innovent Announces First Patient Dosing in Australia in Phas... | ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 18.08.2022 | Innovent Announces First Subject Dosed in Phase 1 Study of I... | SAN FRANCISCO and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 10.08.2022 | Innovent Announces Phase 2 Clinical Study of Picankibart (IB... | SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 08.08.2022 | Innovent Announces First Patient Dosed in Phase 1 Study of I... | SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 04.08.2022 | Press Release: Sanofi and Innovent Biologics enter strategic... | Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology me... | globenewsw... |
| 04.08.2022 | Innovent Biologics and Sanofi Enter Strategic Collaboration ... | Collaboration to accelerate the development and access of oncology medicines for cancer patients in ... | en.prnasia... |
| 01.08.2022 | Innovent and Laekna Jointly Announce First Patient Dosed wit... | SAN FRANCISCO and SUZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 20.07.2022 | Innovent and Ascentage Pharma Announce the China NMPA Accept... | SAN FRANCISCO, ROCKVILLE, Md. and SUZHOU, China, July 20, 2022 /PRNewswire/ -- Innovent Biologics, I... | en.prnasia... |
| 20.07.2022 | Ascentage Pharma and Innovent Announce the China NMPA Accept... | SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- Ascentage Pharma (685... | en.prnasia... |
| 19.07.2022 | Significant Glycemic Control and Weight Loss: Innovent Annou... | SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (... | en.prnasia... |
| 04.07.2022 | Innovent Announces First Patient Dosed in a Phase 2 Clinical... | SAN FRANCISCO and SUZHOU, China, July 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 29.06.2022 | Innovent Announces Phase 1b Study Results of Mazdutide (IBI3... | SAN FRANCISCO and SUZHOU, China, June 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 27.06.2022 | Innovent and Lilly Jointly Announce the Approval of TYVYT® (... | SAN FRANCISCO and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 21.06.2022 | Innovent and Lilly Jointly Announce the Approval of TYVYT® (... | SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc... | en.prnasia... |
| 14.06.2022 | Innovent and Etana Jointly Announce the Approval of Bevagen®... | SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 14.06.2022 | Innovent Announces the NMPA Acceptance of the New Drug Appli... | SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 13.06.2022 | Innovent Releases Results of High-dose Cohorts in Phase 1 Cl... | SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 13.06.2022 | Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cel... | SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
| 08.06.2022 | Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chi... | SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (H... | en.prnasia... |
| 07.06.2022 | Innovent and AnHeart Jointly Present Updated Phase 2 Efficac... | In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate... | en.prnasia... |
| 06.06.2022 | Innovent Presents Clinical Data of Phase I Study for IBI351 ... | SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 06.06.2022 | Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monocl... | SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 06.06.2022 | Innovent and IASO Bio Jointly Announce the NMPA Acceptance o... | SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 02.06.2022 | IASO Bio and Innovent Jointly Announce the NMPA Acceptance o... | SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics (... | en.prnasia... |
| 01.06.2022 | Innovent Appoints Mr. Gary Zieziula as Independent Non-execu... | SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 16.05.2022 | Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 mo... | SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove... | en.prnasia... |
| 14.04.2022 | Innovent Receives NMPA Breakthrough Designation for IBI310, ... | SAN FRANCISCO and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 11.04.2022 | Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 ... | SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 06.04.2022 | Innovent Announces the Approval of Pemazyre® (pemigatinib) b... | SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (... | en.prnasia... |
| 04.04.2022 | Innovent Releases Results of a Phase 3 Clinical Study of IBI... | SAN FRANCISCO and SUZHOU, China, April 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (... | en.prnasia... |
| 30.03.2022 | Innovent Announced 2021 Annual Results | A Harvest Year with Product Revenue over RMB 4Bn
A Pipeline of 32 Valuable Assets with Late Stage Pi... | en.prnasia... |
| 29.03.2022 | Innovent Announces First Patient Dosing of Claudin18.2/CD3 B... | SAN FRANCISCO and SUZHOU, China, March 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno... | en.prnasia... |
| 28.03.2022 | Innovent and Lilly Expand Strategic Partnership in Oncology | SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics,... | en.prnasia... |
| 01.03.2022 | Innovent Biologics and AnHeart Therapeutics Receive NMPA Bre... | SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov... | en.prnasia... |
